These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24866133)

  • 1. One step forward for serelaxin as a promising therapy in cardiac fibrosis.
    Fernández-Alfonso MS; Ruilope LM
    Hypertension; 2014 Aug; 64(2):229-30. PubMed ID: 24866133
    [No Abstract]   [Full Text] [Related]  

  • 2. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease.
    Samuel CS; Bodaragama H; Chew JY; Widdop RE; Royce SG; Hewitson TD
    Hypertension; 2014 Aug; 64(2):315-22. PubMed ID: 24866131
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human H2 relaxin (serelaxin) as a cardiovascular drug: aiming at the right target.
    Bani D
    Drug Discov Today; 2020 Jul; 25(7):1239-1244. PubMed ID: 32360533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.
    Teerlink JR; Cotter G; Davison BA; Felker GM; Filippatos G; Greenberg BH; Ponikowski P; Unemori E; Voors AA; Adams KF; Dorobantu MI; Grinfeld LR; Jondeau G; Marmor A; Masip J; Pang PS; Werdan K; Teichman SL; Trapani A; Bush CA; Saini R; Schumacher C; Severin TM; Metra M;
    Lancet; 2013 Jan; 381(9860):29-39. PubMed ID: 23141816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serelaxin : a potential new drug for the treatment of acute heart failure.
    Neverova N; Teerlink JR
    Expert Opin Investig Drugs; 2014 Jul; 23(7):1017-26. PubMed ID: 24865798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of cardiac fibrosis and related dysfunction by relaxin.
    Du XJ; Xu Q; Lekgabe E; Gao XM; Kiriazis H; Moore XL; Dart AM; Tregear GW; Bathgate RA; Samuel CS
    Ann N Y Acad Sci; 2009 Apr; 1160():278-84. PubMed ID: 19416203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence.
    Ghosh RK; Banerjee K; Tummala R; Ball S; Ravakhah K; Gupta A
    Cardiovasc Ther; 2017 Feb; 35(1):55-63. PubMed ID: 27727514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serelaxin a novel treatment for acute heart failure.
    Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
    Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
    Ng TM; Goland S; Elkayam U
    Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted biological therapies reach the heart: the case of serelaxin for heart failure.
    Kumar VA; Wilson SS; Ayaz SI; Levy PD
    Drugs Today (Barc); 2015 Oct; 51(10):591-7. PubMed ID: 26583301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection.
    Díez J; Ruilope LM
    Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):119-30. PubMed ID: 27418970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension.
    Chunduri P; Patel SA; Levick SP
    Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serelaxin: new investigational treatment in acute heart failure.
    Said S; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):243-8. PubMed ID: 24289727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
    Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
    Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does serelaxin treatment alter passive mechanical wall properties in small resistance arteries?
    Jelinic M; Kahlberg N; Parry LJ; Tare M
    Microcirculation; 2016 Nov; 23(8):631-636. PubMed ID: 27653183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Top heart-failure contender serelaxin flops.
    Nat Biotechnol; 2017 Apr; 35(4):297. PubMed ID: 28398333
    [No Abstract]   [Full Text] [Related]  

  • 17. Relaxin' the Heart: A Novel Therapeutic Modality.
    Raleigh JM; Toldo S; Das A; Abbate A; Salloum FN
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):353-62. PubMed ID: 26589290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Odds still favor Novartis heart failure drug Serelaxin.
    Ratner M
    Nat Biotechnol; 2014 Jul; 32(7):602-3. PubMed ID: 25004210
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin.
    Schmieder RE; Mitrovic V; Hengstenberg C
    Clin Res Cardiol; 2015 Aug; 104(8):621-31. PubMed ID: 25787721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relaxin inhibit cardiac fibrosis induced by phorbol 12-myristate 13-acetate.
    Wang YP; Wang P; Dong L; Chen H; Wu YQ; Li HW; Li M
    Biomed Environ Sci; 2014 Feb; 27(2):138-41. PubMed ID: 24625407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.